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Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an effective ther-
apy for the treatment of high-risk haematological malignant disorders and other 
life-threatening haematological and genetic diseases. Acute graft-versus-host dis-
ease (aGvHD) remains the most frequent cause of non-relapse mortality following 
allo-HCT and limits its extensive clinical application. Current pharmacologic agents 
used for prophylaxis and treatment of aGvHD are not uniformly successful and have 
serious secondary side effects. Therefore, more effective and safe prophylaxis and 
therapy for aGvHD are an unmet clinical need. Defibrotide is a multi-target drug 
successfully employed for prophylaxis and treatment of veno-occlusive disease/
sinusoidal obstruction syndrome. Recent preliminary clinical data have suggested 
some efficacy of defibrotide in the prevention of aGvHD after allo-HCT. Using a fully 
MHC-mismatched murine model of allo-HCT, we report here that defibrotide, either 
in prophylaxis or treatment, is effective in preventing T cell and neutrophil infiltra-
tion and aGvHD-associated tissue injury, thus reducing aGvHD incidence and sever-
ity, with significantly improved survival after allo-HCT. Moreover, we performed in 
vitro mechanistic studies using human cells revealing that defibrotide inhibits leuco-
cyte-endothelial interactions by down-regulating expression of key endothelial ad-
hesion molecules involved in leucocyte trafficking. Together, these findings provide 
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1  | INTRODUC TION
Acute graft-versus-host disease (aGvHD) is the most frequent 
life-threatening complication after allogeneic hematopoietic stem 
cell transplantation (allo-HCT). The pathobiology of aGVHD results 
from immunocompetent allogeneic T cells contained in the mar-
row graft that recognize the recipient as foreign and migrate and 
attack specific host tissues (typically the skin, gastrointestinal tract 
and liver), resulting in significant immune/cytokine-mediated tis-
sue injury, endothelial dysfunction, and high morbidity and mortal-
ity.1-5 Different prophylactic and treatment regimens are currently 
employed to reduce the incidence and severity of aGvHD, most 
commonly based on corticosteroids, calcineurin inhibitors or other 
immunosuppressants. However, responses are unsatisfactory and 
aGvHD remains a significant problem. Thus, there is an unmet need 
for the development of newer strategies to prevent and treat this 
disease.6
Defibrotide is a polydisperse mixture of 90% single-stranded and 
10% double-stranded phosphodiester oligonucleotides derived from 
controlled depolymerization of porcine intestinal mucosal DNA that 
has proved to be effective for prophylaxis and treatment of hepatic 
veno-occlusive disease/sinusoidal obstruction syndrome (VOD/
SOS) following allo-HCT.7,8 It has been proposed to have a protective 
effect on activated endothelial cells,9-11 and among others, pro-fi-
brinolytic, anti-thrombotic and anti-inflammatory activities have 
been reported.12 Defibrotide has been found to suppress hepara-
nase gene expression, whose high levels have been postulated as 
a risk factor for aGvHD development,13,14 and it was initially iden-
tified as an adenosine receptor agonist, whose activation inhibits 
T cell function.10,15,16 Importantly, preliminary evidence in recent 
clinical trials employing defibrotide for VOD suggests that it could 
also have a prophylactic effect on the occurrence of aGvHD after 
allo-HCT: patients who received VOD prophylaxis with defibrotide 
had also a lower incidence and severity of aGvHD than untreated 
control group of patients, and it also did not seem to interfere with 
a graft-versus-leukaemia effect.17,18 Based on these indirect data, 
defibrotide received an orphan designation for the prevention of 
aGvHD. However, its efficacy for the prevention and treatment of 
aGvHD as the only drug without the administration of other immu-
nosuppressant/s, as well as the molecular mechanisms mediating its 
aGvHD-protective effect, has not been previously addressed.
Given such prior findings, we sought the mechanistic basis of 
defibrotide effects on evolving aGvHD. Here, using a murine model 
of fully major histocompatibility complex (MHC)-mismatched al-
lo-HCT to induce fulminant aGvHD, we report that administration 
of defibrotide with same total daily dose employed for VOD in hu-
mans is also effective for both prophylaxis and treatment of murine 
aGvHD. This effect is mediated via a significant early inhibition of 
donor alloimmune effector T cell and neutrophil tissue infiltration, a 
substantial decrease in aGvHD-associated tissue injury, and a rever-
sal of plasma pro-inflammatory/anti-inflammatory cytokines ratios. 
These effects yield a significant increased survival. Mechanistic in 
vitro studies using human samples reveal that defibrotide inhibits 
peripheral blood leucocyte transendothelial migration by down-reg-
ulating expression of key endothelial adhesion molecules involved 
in leucocyte trafficking such as E-selectin, P-selectin, ICAM-1 and 
VCAM-1. Collectively, these findings provide novel perspectives on 
the clinical applicability of this multi-target drug in aGvHD therapy 
following allo-HCT.
2  | MATERIAL S AND METHODS
2.1 | Mice
BALB/c (H-2Kd, CD45.2) and C57BL/6J (H-2Kb, CD45.2) mice were 
purchased from Envigo Harlan (Huntingdon, Cambridgeshire, United 
Kingdom). At the time of allo-HCT, mice were aged 10-12 week. 
Housing was maintained under specific pathogen-free conditions in 
the animal facilities of the University of Murcia. All animal protocols 
were approved by the Institutional Animal Care and Use Committee 
at University of Murcia (protocol A13150201).
2.2 | Induction and assessment of murine 
aGvHD and histopathology analysis
A model of fully MHC-mismatched allo-HCT was carried out by 
transplanting bone marrow mononuclear cells from donor BALB/c 
mice into recipient C57BL/6J mice that were previously irradiated 
by with a lethal dose of 10 Gy split into two equal doses of 5 Gy and 
24 hours apart (days −1 and +0). To induce aGvHD, on day +0 recipi-
ent C57BL/6J mice were injected intravenously with 1 × 107 bone 
marrow mononuclear cells from donor BALB/c mice and 1.5 × 107 
BALB/c donor splenocytes. Mice survival post-transplant was 
monitored daily, and clinical aGvHD was evaluated using a scoring 
evidence that defibrotide may represent an effective and safe clinical alternative for 
both prophylaxis and treatment of aGvHD after allo-HCT, paving the way for new 
therapeutic approaches.
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system that generates a composite aGvHD score composed of in-
dividual scores for weight loss, posture, activity, skin integrity and 
fur texture.19
Histopathology analysis of aGvHD was performed in different 
sections of liver, intestine (colon), skin and oral mucosa (tongue) col-
lected from the recipients 10 days after allo-HCT and analysed as 
described previously19,20 by a single pathologist blinded to the treat-
ment groups. Samples from the different organs were fixed in for-
malin and embedded in paraffin. After, three-micrometre sections 
were stained with haematoxylin and eosin stain for histopathologic 
examination. In brief, the skin histopathologic lesions were grade 0 
(normal), grade I (slight vacuolar degeneration of epidermal basal 
cells), grade II (scattered individual apoptotic epidermal basal cells, 
spongiosis), grade III (separation of dermoepidermal junction) and 
grade IV (diffuse and severe ulceration, with extensive destruction 
of epidermis). Colon aGvHD scores were either grade 0 (normal), 
grade I (scattered individual apoptotic cells, with inflammatory cell 
infiltrate), grade II (crypt epithelial cell apoptosis, with villous blunt-
ing and/or exploding crypts), grade III (focal mucosal ulceration, with 
moderate villous atrophy) and grade IV (diffuse and severe muco-
sal ulceration). Liver aGvHD was scored according to degree of bile 
ducts affected: 0 (normal), grade I (≤25% bile ducts affected), grade 
II (25%-49% bile ducts affected), grade III (50%-74% bile ducts af-
fected) and grade IV (≥75% bile ducts affected). The scoring system 
used for histopathologic evaluation of the tongue samples was based 
on intraepithelial inflammatory infiltrate as follows: grade 0 (ab-
sence of inflammatory infiltrate), grade 1 (weak), grade 2 (moderate), 
grade 3 (intense) and grade 4 (severe). The degree of T-lymphocyte 
infiltrate or induction of apoptosis was evaluated by immunohisto-
chemical labelling by using a commercial kit (EnVision Flex, Dako-
Agilent Technologies, Barcelona, Spain). Briefly, tissue sections were 
submitted to deparaffinization and rehydration, followed by antigen 
demasking procedure and endogenous peroxidase inhibition. After, 
sections were incubated with primary antibodies (anti–T-CD3, Dako) 
for 1 hour at 37ºC, following by secondary anti-rabbit labelled poly-
mer incubation for 20 minutes at 37ºC. Immunoreaction was finally 
revealed by incubation with 3-3´diaminobenzidine (Sigma-Aldrich, 
St. Louis, MO). Positive immunoreaction was identified as a dark-
brown pericellular staining. In addition, polymorphonuclear (PMN) 
neutrophils were identified on H&E-stained sections according to 
morphologically evident segmented nuclei. All analyses were per-
formed by using a standard direct-light microscope (Axio A10, Carl 
Zeiss, Barcelona, Spain).
2.3 | Defibrotide administration
Defibrotide solution was provided by Gentium SpA, Jazz 
Pharmaceuticals (Dublin, Republic of Ireland). Defibrotide was sus-
pended in saline solution at a concentration of 2,5 µg/µL to reach 
25 mg/kg bodyweight, and 200-250 µL was injected intraperito-
neally (i/p) as a single dose as prophylaxis (day −2 to day +17 post-
allo-HCT) or treatment (day +7 to day +27 post-allo-HCT).
Untreated controls were injected daily with same volume of sa-
line solution without defibrotide.
2.4 | Determination of plasmatic cytokines by 
enzyme-linked immunosorbent assays (ELISA)
Murine IFNγ, TNFα, IL-6, IL-12, TGFβ and IL-10 were measured in 
blood plasma by ELISA (Diaclone, bioNova Cientifica, Madrid, Spain; 
and Elabscience, Bethesda, MD). All experimental samples and 
standards were assayed in triplicate according to the manufacturer's 
instructions.
2.5 | Cell cultures
SK-Hep1, an immortalized human endothelial cell line derived 
from ascitic fluid, and primary human umbilical vein endothelial 
cells (HUVEC) were used to investigate defibrotide effects on en-
dothelial adhesion molecule expression and human leucocyte ad-
hesion/transendothelial migration in vitro. SK-Hep1 was cultured 
in Eagle's Minimum Essential Medium (Sigma-Aldrich) containing 
10% foetal bovine serum (Gibco, Carlsbad, CA), 1% L-glutamine 
(Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco) 
at 37ºC and 5% CO2. Cells were used between the tenth and fif-
teenth passages.
HUVEC were isolated from human umbilical veins and cul-
tured in Endothelial Cell Growth Medium (PromoCell, Heidelberg, 
Germany) at 37ºC and 5% CO2 according to the manufactur-
er's instructions. Cells were used between the second and third 
passages.
Human peripheral blood mononuclear cells (MNCs) were iso-
lated using Ficoll-Paque density gradient centrifugation from hep-
arinized blood samples obtained from healthy volunteers after 
informed consent. In some experiments, pooled sera samples ob-
tained from three different patients with aGvHD on the day of 
diagnosis, or from same number of healthy donors, were used. 
Hospital Virgen de la Arrixaca and Hospital Clinic de Barcelona 
Ethics Committees approved the protocols used to obtain and pro-
cess all human samples.
2.6 | Parallel-plate flow chamber adhesion assays
The effects of defibrotide on leucocyte adhesion on endothelial 
cells were analysed using a parallel-plate perfusion chamber. SK-
Hep1 monolayers were treated previously with 100 µg/mL defib-
rotide for 24 hours or left untreated and then grown for 48 hours 
in medium supplemented with 20% pooled sera of aGvHD patients 
(n = 15, Table 1) or of healthy donors (n = 15). Then, SK-Hep1 cells 
were perfused with control citrated blood from a healthy donor at 
a shear rate of 300 s−1 for 10 minutes. After perfusion, coverslips 
were washed with PBS and fixed in 3% paraformaldehyde in PBS. 
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For leucocyte immunostaining, coverslips were treated with 1% 
BSA, permeabilized with 0.1% Triton-X and stained with an anti-
human CD45 antibody (Abcam), followed by Alexa488-conjugated 
anti-rabbit secondary antibody (Life Technologies, Carlsbad, CA), 
and PE-conjugated anti-human CD3 (BD Biosciences, San Jose, CA) 
and DAPI (Sigma-Aldrich) for nuclei counterstaining. Finally, cover-
slips were visualized by fluorescent microscopy (Leica-DM4000B) 
through a video camera (Leica-DFC310FX) and analysed using 
ImageJ software (National Institutes of Health, Bethesda, MD). The 
number of adherent leucocytes and T cells was expressed as per-
centage related to the total number of endothelial cells (number of 
leucocytes per 100 endothelial cells).
2.7 | Transwell migration assays and flow 
cytometry analysis
HUVEC in culture were exposed to medium containing 20% pooled 
sera of aGvHD patients (n = 4, Table 1) or of healthy donors (n = 4) 
for 48 hours and incubated with 100 µg/mL defibrotide (treat-
ment), or alternatively, by previous exposure to defibrotide for 
24 hours followed by continuous incubation (100 µg/mL, added 
every 24 hours) before exposition to sera (prophylaxis). Afterwards, 
7.5 × 104 HUVEC were seeded onto the upper chamber of Transwell 
filters with 5-µm pores (NUNC, Roskilde, Denmark). Then, 3 × 105 
peripheral blood MNCs or T-CD3 cells (obtained by magnetic selec-
tion using Pan human T cell isolation kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany)) were resuspended in 100 µL of DMEM me-
dium (Sigma-Aldrich) containing 0.3% bovine serum albumin (BSA) 
(Sigma-Aldrich) and added to the upper chamber. The lower chamber 
contained DMEM medium supplemented with 0.3% BSA and 20% 
pooled sera of aGvHD patients/healthy donors as chemoattractant 
stimulus. Next, cells were allowed to migrate for 16 hours at 37ºC. 
Finally, the extent of cell migration was analysed using an automated 
cell counter (Bio-Rad TC20, Hercules, CA). All experimental condi-
tions were analysed in triplicate.
For flow cytometry analysis, HUVEC were detached with tryp-
sin-EDTA (Gibco), resuspended in PBS containing 1% BSA and in-
cubated with fluorescence-labelled anti-human antibodies specific 
for E-selectin, P-selectin, VCAM-1 and ICAM-1 (all from eBioscience, 
San Diego, CA), or their control isotype antibodies for 30 minutes in 
the dark at 4ºC. Finally, cells were washed twice and acquired in a 
FACSCanto flow cytometer (BD Biosciences, San Jose, CA).
2.8 | Statistical analysis
Results are expressed as mean ± standard deviation. Student's paired 
t test or one-way ANOVA followed by Bonferroni's post hoc com-
parison tests was used for statistical comparisons between groups. 
Survival curves were plotted using Kaplan-Meier estimates and sta-
tistically analysed using the Mantel-Cox log-rank test. P values < .05 
were considered statistically significant.
3  | RESULTS
3.1 | Defibrotide aGVHD treatment reduces aGvHD 
clinical manifestations and reduces level of donor T 
cell and PMN neutrophil infiltrates in aGvHD-target 
organs
To test the hypothesis that defibrotide has direct effects in aGvHD 
onset and/or evolution, mice with ongoing aGvHD (from day +7 
after allo-HCT) were treated with a daily i/p infusion of 25 mg/
kg of defibrotide for 20 days, following the same total daily dose 
used in human VOD/SOS patients (schematic diagram shown in 
Figure 1A). Control mice receiving allo-HCT (BM transplant, that 
is receiving donor BALB/c bone marrow cells w/o splenocytes) and 
mice receiving syngeneic transplant (ie transplanted with bone 
marrow cells and splenocytes from donor C57BL/6J) did not de-
velop aGvHD, whereas mice receiving allo-HCT plus donor BALB/c 
splenocytes without defibrotide treatment (ie ‘untreated’ group) 
showed a rapid severe aGvHD occurrence, which caused the early 
death in all mice (Figure 1C). However, daily administration of defi-
brotide showed a significantly lower aGvHD-related mortality than 
untreated mice group (P < .001) (60% survival in defibrotide group 
versus 0% survival in untreated group at day +60 post-transplan-
tation, P < .001) (Figure 1C). Also, defibrotide-treated mice signifi-
cantly improved their clinical aGvHD score compared to untreated 
mice group, being significantly lower from the onset of the disease 
(P < .001) (Figure 1D). To evaluate whether defibrotide had effects 
in the prophylaxis of aGVHD, mice were treated with a daily intra-
peritoneal infusion of 25 mg/kg of defibrotide from 2 days before 
allo-HCT to 17 days after (schematic diagram shown in Figure 1B). 
Remarkably, mice receiving daily prophylaxis with defibrotide dis-
played a high survival advantage over the untreated mice group 
(P < .001) (87.5% survival in defibrotide group versus 0% survival 
in untreated group at day +60 post-transplantation) (Figure 1E), 
also showing a significant reduction in aGvHD clinical score dur-
ing aGvHD evolution compared to untreated group of animals 
(P < .001) (Figure 1F). These in vivo results suggest that defibrotide 
can mitigate the severity of early-stage aGvHD, both as the only 
prophylaxis or treatment drug.
To determine the impact of defibrotide on reversal of aGvHD, 
a histopathology analysis was performed in the main aGvHD-tar-
get organs (skin, liver, colon and tongue) in animals receiving pro-
phylactic defibrotide infusions after allo-HCT (Figure 2). On day 
+10 post-transplantation, untreated mice displayed skin vacuolar 
degeneration and scattered apoptotic epidermal basal cells (grade 
0-I), whereas there were no patent lesions on the skin of the de-
fibrotide-treated, BM transplant or syngeneic (Syn)-HCT animals. 
Histological examination of liver and colon displayed significant 
differences in the aGvHD severity between both experimental 
and control groups of animals. Whereas livers of untreated ani-
mals displayed an extensive epithelial damage, abundant peripor-
tal inflammatory infiltrate and destruction of the majority of bile 
ducts (grade II-III), defibrotide-treated group showed much lower 
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aGvHD-related hepatic epithelium damage (grade 0-I). Also, colon 
of untreated mice showed moderate villous atrophy, interstitial 
inflammatory cell infiltrate and crypt epithelial cell apoptosis 
(grade II-III), whereas those from animals receiving prophylactic 
defibrotide only displayed a slight inflammatory infiltrate and 
scattered apoptotic cells (grade I). In addition, the tongue was also 
analysed as a representative tissue of oral mucosa, which is also 
affected during aGvHD progression (Figure 2). Tongue dermis of 
untreated animals displayed a weak or moderate inflammatory in-
filtrate (grade 0-I), which was absent in defibrotide-treated mice. 
These observations suggest that the improved survival observed 
in the group of animals receiving defibrotide was correlated with 
a substantially reduced degree of tissue-specific destruction.
Tissue damage in aGvHD-target organs is largely related with 
the ability of alloreactive donor T cells to traffic and infiltrate spe-
cifically these tissues.21-23 Thus, we next investigated levels of 
T-CD3+ cell infiltrates in skin, liver, colon and tongue of untreated 
animals as compared to animals receiving prophylactic defibrotide 
at day +10 after allo-HCT. Significantly, we observed that livers, 
colon and tongues of untreated allo-HCT recipients displayed sig-
nificant higher levels of T-CD3+ infiltrates than BM transplanted or 
syn-HCT animals. However allo-HCT mice that received defibrot-
ide showed a substantial decrease in T-CD3+ infiltrates compared 
to their untreated counterparts, mainly in the colon (P < .001) 
(Figure 3A,B). On the other hand, skin sections of mice among the 
two groups of animals only displayed scattered infiltrates of donor 
T cells, which correlated with no observable lesions in this tissue at 
this time post-transplantation.
Apart from tissue trafficking of T cells, it has been previously 
described that neutrophils can also infiltrate the aGvHD-target 
organs, being considered as a bad prognostic marker of early al-
lo-HCT–associated mortality.24 As such, we also examined the 
level of neutrophil infiltrates in aGvHD-target organs of all groups 
of animals. Although at day +10 post-transplant mice remain still 
neutropenic, there were significantly reduced neutrophil infiltrates 
in skin, liver and colon of mice receiving prophylactic defibrotide 
F I G U R E  1   Defibrotide treatment or prophylaxis reduces the incidence and severity of aGvHD in mice undergoing a fully MHC-
mismatched allo-HCT. After aGvHD onset (from day +7 after allo-HCT), mice were treated with a daily administration of 25 mg/kg of 
defibrotide for 20 d or with 25 mg/kg of prophylactic defibrotide from 2 d before allo-HCT to 17 days after. Schematic diagrams of the 
experimental protocols of defibrotide treatment (A) or prophylaxis (B) after allo-HCT are shown. Untreated mice received same doses and 
volume of saline solution. C,D, Kaplan-Meier survival curves and aGvHD clinical score of recipient C57BL/6J treated with defibrotide after 
aGvHD onset or (E,F) receiving prophylactic defibrotide are shown, respectively. Survival or aGvHD clinical score was significantly higher 
compared to untreated group, ***P < .001. Results are representative of n = 3 separate experiments, n = 8 mice per experimental group
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compared to untreated counterparts after allo-HCT, P < .001 
(Figure 3C,D).
Importantly, control experiments revealed that peripheral blood 
lymphocytes and neutrophils counts in untreated mice and mice re-
ceiving defibrotide were parallel, indicating that the different degrees 
of tissue infiltration of both immune populations were not a conse-
quence of a different leucocyte engraftment after allo-HCT (data not 
shown).
3.2 | Prophylactic administration of defibrotide 
reverses ratios of plasma pro-inflammatory and anti-
inflammatory cytokines
To further evaluate the effects of defibrotide administration on 
aGvHD development, we analysed the release of several pro-
inflammatory cytokines described to have key roles during the 
effector phase of aGVHD.25 Mice with ongoing aGvHD after 
F I G U R E  2   Histopathological assessment of aGvHD in mice receiving prophylactic defibrotide. Main histopathological aGvHD signs 
were analysed in skin, liver, colon and tongue of all groups of transplanted mice: BM transplant (w/o splenocytes), syngeneic transplant 
(syn-HCT) and allo-HCT mice, this last group including untreated mice or animals receiving prophylactic defibrotide at day +10 post-
transplantation. Skin: vacuolar degeneration and scattered apoptotic epidermal basal cells (yellow arrowhead); liver: 50%-75% of bile ducts 
surrounded by inflammatory cell infiltrate and epithelial damage (black arrowhead), or >75% of unaffected bile ducts (red arrowhead); colon: 
moderate villous atrophy (+), interstitial inflammatory cell infiltrate (yellow asterisk), crypt epithelial cell apoptosis (black asterisk), or slight 
inflammatory infiltrate and scattered apoptotic cells (yellow arrowhead); and tongue: weak or moderate inflammatory cell infiltrate (yellow 
asterisk). H&E staining images from the different organs shown (magnification ×200) are representative of n = 8 animals per group. Scale 
bar: 50 µm
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allo-HCT and without defibrotide administration (ie untreated 
animals) displayed significant increases in plasma pro-inflam-
matory cytokines such as IFNγ, TNFα, IL-6 and IL-12 on day +10 
post-transplantation compared to syn-HCT control group (w/o 
aGvHD) (P < .001), with simultaneous reduced concentrations of 
anti-inflammatory TGFβ and IL-10 (Figure 4). However, defibrotide 
prophylactic daily administration induced a marked decrease in 
these pro-inflammatory mediators (P < .01, P < .001) and signifi-
cant increased levels of the anti-inflammatory cytokines TGFβ and 
IL-10 (P < .01) (Figure 4).
F I G U R E  3   Defibrotide prophylactic administration significantly decreases donor T cell and PMN neutrophil infiltration in aGvHD-target 
organs after allo-HCT. Tissues from the different groups of animals, BM transplant (BMT), syn-HCT (SYN) or allo-HCT (either untreated 
(UNT) or receiving prophylactic defibrotide (DF)), were isolated 10 d after transplant. A, B, T cell infiltrates were detected by standard ABC 
anti-CD3 immunohistochemistry procedure. C, D, Polymorphonuclear (PMN) neutrophils were identified in the different tissue sections on 
the basis to its morphological features (nuclear segmentation). Representative images of the skin, liver, colon and tongue from the different 
mice groups showing T-CD3+ or PMN neutrophil infiltrates (red arrows) are shown (magnification ×200 or ×400, respectively) (n = 8 animals 
per group, n = 3 separate experiments). Scale bar: 50 µm. Absolute T-CD3+ cell or PMN neutrophil counts are presented as mean ± SD per 
high-power field from counts relative to 10 high-power fields (magnification ×200 or ×400, respectively). T-CD3+ cell or PMN neutrophil 
infiltrates were significantly increased compared to syn-HCT group, **P < .01, ***P < .001, or decreased compared to untreated allo-HCT 
group, ∆∆∆P < .001, respectively
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3.3 | Defibrotide impairs human leucocyte 
trafficking and down-regulates endothelial adhesion 
molecules expression: mechanism of action involved 
in the protective effect of defibrotide.
Acute GvHD is associated with the up-regulation of several endothe-
lial cell adhesion molecules such as E-selectin, P-selectin, VCAM-1 
and ICAM-1 in the affected organs in response to the effect of pro-
inflammatory cytokines, favouring donor alloreactive leucocytes to 
engage the endothelium and extravasate to the target tissue(s).26-28 
In order to extrapolate the findings obtained in the aGvHD murine 
model to the human disease, we first analysed whether defibrotide 
interferes with peripheral blood MNC or T cell adhesion and migra-
tion on endothelial HUVEC and SK-Hep1 cell lines. As previously re-
ported,11 defibrotide does not interact with peripheral blood MNCs, 
and when leucocytes were directly incubated with defibrotide, 
leucocyte-endothelial rolling adhesive interactions under hemody-
namic flow conditions were not affected (data not shown). However, 
subsequent Transwell migration assays showed that when HUVEC 
were exposed to aGvHD sera and treated with defibrotide after-
wards (Figure 5A) or before (Figure 5B), transendothelial migration 
of MNCs and T-CD3 cells was significantly inhibited as compared to 
the levels of migration observed using untreated HUVEC (P < .001). 
Also, parallel-plate perfusion chamber experiments showed that 
previous exposure of endothelial SK-Hep1 cells to defibrotide signif-
icantly prevented MNCs and T-CD3 rolling interactions and subse-
quent firm adhesion under hemodynamic flow conditions compared 
to untreated endothelial cells (P < .01 and P < .05, respectively) 
(Figure 5C,D).
The observed decreased interactions between leucocytes and 
endothelial cells suggest that defibrotide could modulate expres-
sion of key adhesion molecules involved in the sequential cascade 
of events that control migration of leucocytes from vascular to ex-
travascular compartments. To this end, we analysed expression of 
E-selectin, P-selectin, VCAM-1 and ICAM-1 on HUVEC previously 
treated or not with defibrotide and after being stimulated with the 
F I G U R E  4   Defibrotide prophylaxis modifies the systemic profile of secreted plasma pro-inflammatory and anti-inflammatory cytokines 
on mice with ongoing aGvHD after allo-HCT. Plasma concentrations of the pro-inflammatory cytokines IFNγ, TNFα, IL-6 and IL-12, and anti-
inflammatory TGFβ and IL-10 were determined on the different groups of animals, BM transplant (BMT), syn-HCT (SYN) or allo-HCT (either 
untreated (UNT) or receiving prophylactic defibrotide (DF)), on day +10 post-transplant. Data are presented as mean ± SD of n = 5 animals 
per group and n = 3 separate experiments. Levels of each cytokine were significantly up-regulated compared to SYN group, ***P < .001, or 
significantly down- or up-regulated compared to SYN group, ∆∆∆P < .001, respectively
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aGvHD sera. Whereas untreated HUVEC displayed a significant 
marked up-regulation of all these adhesion molecules (P < .001), pre-
vious incubation of HUVEC with defibrotide significantly down-reg-
ulates expression of E-selectin, P-selectin, VCAM-1 and ICAM-1 
(P < .01, P < .001) (Figure 5E,F). Collectively, these results indicate 
that defibrotide protective function in endothelium includes the 
down-regulation of expression of endothelial adhesion molecules 
highly overexpressed during aGvHD, which could prevent the sub-
sequent in vivo donor leucocyte extravasation to target tissue(s).
4  | DISCUSSION
Allogeneic HCT provides a replacement of the diseased marrow 
with healthy hematopoietic progenitor cells derived from the donor. 
Moreover, allo-HCT is an important type of adoptive cell immuno-
therapy in which donor alloreactive immune cells confer a potent 
graft-versus-malignancy effect. However, it can also induce immu-
nopathological processes such as aGvHD, which is related to the im-
munologic recognition and destruction of specific host tissues that 
notably increase the mortality of the procedure.29
In the present study, we provide evidence on the therapeutic ef-
ficacy of defibrotide in prevention and treatment of aGvHD after 
allo-HCT. Although two preliminary clinical studies have suggested 
indirect evidence that defibrotide prophylaxis might decrease the 
risk of aGvHD in paediatric and adult patients receiving allo-HCT,17,18 
this is the first comprehensive preclinical study demonstrating that 
administration of defibrotide as a single agent, without other con-
comitant treatment, is sufficient to effectively prevent and/or treat 
this immunopathological complication.
Defibrotide has been previously described as a multi-target 
drug, showing anti-thrombotic/thrombolytic, anti-ischaemic, pro-fi-
brinolytic and anti-angiogenic effects.30-34 But defibrotide has also 
demonstrated important anti-inflammatory properties and a pro-
tective effect on endothelial cells from HCT conditioning.12,35,36 
These findings and the fact that aGvHD occurrence is associated 
with higher activation and dysfunction of endothelial cells37 led us 
to hypothesize that defibrotide may be an effective agent for aGvHD 
prevention and/or treatment.
Our findings indicate that daily infusions of defibrotide employ-
ing the same total daily dose as in human VOD/SOS patients, given 
prior to allo-HCT (prophylaxis) or once aGvHD has already devel-
oped (treatment), significantly dampened the severity of aGvHD, 
resulting in a much lower aGvHD clinical score and a markedly 
improved survival. Importantly, histological analysis demonstrates 
that infusions of defibrotide markedly restrain aGvHD-target organ 
damage, particularly in the liver and colon compared to those that 
did not receive any treatment. Nevertheless, this allo-HCT model 
did not allow evaluating the efficacy of defibrotide in reversing 
skin aGvHD. Skin manifestations are a frequent early complica-
tion during human evolving aGvHD.38 However, many studies 
point out that the choice of mouse strains to be used as donors 
and recipients of allo-HCT greatly affects the development of the 
subsequent clinical manifestations of aGvHD due to differences in 
their immune triggering mechanisms (ie mismatches in major and 
minor histocompatibility complex molecules, effector T cell sub-
populations involved or different production of pro-inflammatory 
mediators).39,40 Thus, these specific differences in spatio-tempo-
ral GvHD-target organ involvement depend largely on the murine 
model of HCT employed.
During the effector phase of aGvHD, donor effector T cells at-
tack the recipient after recognizing the host tissues as antigenically 
foreign.23,41 As expected, animals receiving allo-HCT that devel-
oped aGvHD displayed high levels of T cell infiltrates in aGvHD-tar-
get organs at early time post-allo-HCT (by day +10), mainly in liver 
and colon. However, mice receiving defibrotide prophylaxis before 
transplant displayed a marked and significant reduction of T cell 
infiltrates.
After T cell recruitment, aGvHD-target organs are also infiltrated 
by other immunocompetent cells of the myeloid lineage, that is neu-
trophils, in a complementary innate pathway in which cognate T cell-
MHC interactions are not needed. Previous studies have revealed 
that an abundance neutrophil infiltrates in host tissues contribute 
synergistically to increase aGvHD severity and related mortality by 
F I G U R E  5   Defibrotide inhibits human peripheral blood MNC and T cell migration and down-regulates endothelial adhesion molecules 
expression. A, HUVEC were exposed to culture medium containing pooled sera of aGvHD patients or from healthy donors (control) and 
treated with defibrotide, or (B) incubated with defibrotide before adding sera (prophylaxis). Then, peripheral blood MNC and T-CD3 cell 
transendothelial migration towards aGvHD or control sera were analysed in Transwell assays in the presence or absence (‘untreated’, ie 
UNT) of defibrotide. Data are expressed as percentages of migrated cells related to the total number of MNCs or T-CD3 cells added to 
the upper chamber. Migration was significantly increased in the aGvHD condition, ***P < .001, or significantly inhibited after defibrotide 
incubation, ∆∆∆P < .001, respectively. C, Also, effect of defibrotide on the MNC or T-CD3 cell rolling and firm adhesion on SK-Hep1 cells 
was analysed using a parallel-plate perfusion chamber under dynamic flow conditions. Adhesion was significantly increased in the aGvHD 
condition, **P < .01, ***P < .001, and significantly inhibited after defibrotide incubation, ∆P < .05, ∆∆P < .01, respectively. D, Representative 
micrographs showing adherent leucocytes (green staining with Alexa488-conjugated anti-human CD45, red staining with PE-conjugated 
anti-CD3 and blue staining with DAPI) obtained in the different experimental conditions are shown (magnification ×40). After, expression of 
endothelial adhesion molecules on HUVEC exposed to pooled aGvHD sera with DF or without prophylactic defibrotide (UNT) was analysed 
by flow cytometry. E, Representative histograms showing E-selectin, P-selectin, VCAM-1 and ICAM-1 expression on HUVEC in the different 
experimental conditions are shown. F, Relative expression of the different adhesion molecules was normalized to untreated HUVEC (ie w/o 
prophylactic defibrotide) incubated with healthy donor pooled sera (UNT control). Expression was up-regulated in the aGvHD condition 
compared to UNT control, ***P < .001, or down-regulated compared to UNT aGvHD, ∆∆P < .01, ∆∆∆P < .001, respectively
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production of reactive oxygen species that leads to T cell activation 
and subsequent potentiation of the tissue damage, mainly in the gas-
trointestinal tract.24,42 In this study, we also found that similarly to 
what was observed with T cells, mice treated with prophylactic in-
fusions of defibrotide showed markedly lower neutrophils infiltrates 
than allo-HCT untreated mice.
The pathogenesis of aGvHD is closely linked to cytokines pro-
duced by T cells and other immune cells that infiltrate aGvHD-tar-
get organs.43,44 Here, we found that mice receiving prophylactic 
defibrotide displayed significant decreased systemic concentra-
tions of a variety of pro-inflammatory cytokines (ie IFNγ, TNFα, 
IL-6 and IL-12) as compared to allo-HCT untreated animals, to-
gether with an increased production of anti-inflammatory TGFβ 
and IL-10. These data reveal that the administration of defibrotide 
prior to the aGvHD onset is sufficient to attenuate the systemic 
inflammation associated with aGvHD. This ‘shift’ in systemic cyto-
kine levels from a pro-inflammatory to an anti-inflammatory profile 
has been described to have an important role in the improvement 
of the systemic inflammatory condition in several immune-me-
diated pathologies, favouring the achievement of peripheral im-
munotolerance.45,46 Moreover, modulation of systemic cytokines 
could down-regulate the expression of endothelial adhesion mole-
cules involved in the trafficking of alloreactive immune cells to the 
aGvHD-target tissues.47,48
Extravasation of circulating leucocytes across vascular wall in-
volves a multistep adhesive interactions mediated by several mole-
cules: a) selectins that mediate first tethering contacts and rolling; b) 
chemokines that mediate inside-out integrin activation and c) inte-
grins that mediate firm adhesion, crawling and subsequent transen-
dothelial migration. It has been demonstrated in in vitro experiments 
and in vivo animal models that defibrotide decreases leucocyte ex-
travasation by down-regulating expression of endothelial P-selectin 
or by interfering with the interaction between the integrin LFA-1 and 
its endothelial ligand ICAM-1.49-52 Recent findings have also revealed 
that defibrotide suppresses the up-regulated expression of VCAM-1, 
ICAM-1, VE-cadherin and von Willebrand factor in endothelial cells 
exposed to sera from aGvHD patients.53 These reported findings, 
together with the observed results in our in vivo model of allo-HCT 
and aGvHD, led us to hypothesize that the protective mechanism of 
action of defibrotide could be related to interruption of adhesive in-
teractions between circulating lymphocytes and endothelium. With 
the purpose of extrapolating our in vivo results to what would occur 
in the human aGvHD condition, we studied whether defibrotide may 
affect cell-surface expression of adhesion receptors on human en-
dothelial cells, as well as its effects on human leucocyte adhesion 
and migration. Our results provide direct evidence that defibrotide 
down-regulates the expression of critical endothelial molecules in-
volved in leucocyte recruitment into tissues (ie P-selectin, E-selectin, 
VCAM-1 and ICAM-1) during aGvHD. This mechanism, together with 
the observed in vivo impairment in leucocyte adhesion and migration 
under the defibrotide effects, could underlie the observed improved 
clinical outcome of mice with aGvHD that received defibrotide.
In summary, our findings indicate that defibrotide, used as a 
concomitant prophylactic or therapeutic drug to the usual stan-
dard immunosuppressants employed for aGvHD, is effective in 
ameliorating the inflammatory response and tissue damage associ-
ated with this immunopathological disease, reducing its incidence 
and severity and significantly improving survival after allo-HCT. 
In addition, defibrotide is not associated with relevant secondary 
side effects associated with other established treatments such 
as with corticosteroids. Therefore, defibrotide might represent a 
promising option for the prophylaxis and treatment of aGvHD in 
patients receiving allo-HCT.
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